Overview

Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Adjuvant Chemotherapy in the Treatment of the Lymph Node Positive Thoracic Esophageal Squamous Cell Carcinoma

Status:
Recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

Esophageal cancer is a highly aggressive malignancy with a poor overall outcome. - Five year survival rate after radical esophagectomy is modest at about 40%.The patients with regional lymph node metastases have worse outcome than those without lymph node metastases. - No standard postoperative adjuvant chemotherapy has ever been established.

Phase:

Phase 3

Details

Lead Sponsor:

Chinese Academy of Medical Sciences

Treatments:

Albumin-Bound Paclitaxel
Cisplatin
Paclitaxel